Community Oncologists Use AI, But Reimbursement, Training, Funding, ROI Stifle Wider Adoption
Johnson & Johnson’s Oncology Care Index finds that many community oncologists use AI tools in their practices, but face significant barriers in closing the gap between innovation and daily care. Medtech Insight spoke with leading oncologists Prerna Mewawalla and Douglas Flora for more insights.
Medtech Insight - September 23, 2026

Enveda To Dig Deeper As It Mines Nature For Drugs Using AI
The company announced it had raised $311m in a series E funding round, which it plans to use to move its lead candidates into later-stage trials.
Scrip - September 23, 2026

DOJ, EPA Reach Proposed Settlement With Puerto Rican Sterilizer Firm Over EtO Violations
The DOJ and EPA have proposed a $700,000 settlement with medical-device sterilizer Steri-Tech over alleged Clean Air Act violations at its Puerto Rico facility. The agreement, which would require the company to reduce ethylene oxide emissions by 99.99%, follows years of EPA scrutiny and enforcement.
Medtech Insight - September 23, 2026

Immunovant FcRn Misses In CLE, But All Eyes On Late-Stage Studies
A Phase II proof-of-concept trial for imeroprubart in cutaneous lupus erythematosus missed the primary endpoint, but investors are focused on later-stage catalysts.
Scrip - September 23, 2026

China R&D Will Continue To Transform Biopharma – As Partner And Rival
The Sidley healthcare investment conference in London heard from GSK and others about China biotech's growing role – and its expected evolution as partner and rival to firms in Europe, Japan and the US.
Scrip - September 23, 2026

UK Set To Become First Country In The World To Authorize CBD Dietary Supplements
Great Britain is set to become the first market to authorize CBD as a food, with three applications now heading to ministers and five years exclusivity the prize for what has been a "costly, onerous and lengthy" process.
HBW Insight - September 23, 2026

Fortunes Turn For Roche’s Sefaxersen As IgAN Pivot Yields Phase III Win
After faltering in eye disorders, the factor B-targeting antisense drug cut proteinuria in Phase III, setting up a challenge to Novartis’s Fabhalta.
Scrip - September 23, 2026

Two Lutathera Rivals Put Novartis’ Radioligand Stronghold To The Test
Lantheus and Curium have brought the first US follow-on competition to Lutathera, setting up a real-world test of whether radiopharmaceutical supply complexity can temper the erosion seen with conventional generics.
Generics Bulletin - September 23, 2026

Senseonics Widens Its AID Reach With Beta Bionics As Pump Integrations Become The Growth Path
Senseonics is pairing its year-long implantable glucose sensor with Beta Bionics' iLet insulin-delivery system, targeting a Q4 2026 launch in a deal built entirely on technical compatibility.
Medtech Insight - September 23, 2026

Novo CEO Doustdar Insists On Disciplined Dealmaking
The Danish company is looking to rebuild investor confidence and M&A is a major pillar in achieving that.
Scrip - September 23, 2026

Teva Bolsters Schizophrenia Franchise Case As Olanzapine Decision Nears
Teva has unveiled fresh Uzedy and olanzapine data as it builds a broader long-acting injectable schizophrenia franchise, while outlining the commercial infrastructure and payer hurdles shaping the products’ growth prospects.
Generics Bulletin - September 23, 2026

Kent Divestment To Phoenix Follows Private-Equity Playbook
Private-equity firm Duke Street has struck a deal to divest value-added medicines business Kent Pharmaceuticals to Irish player Phoenix Labs, expanding Phoenix’s operations in the UK.
Generics Bulletin - September 23, 2026

Biopharma’s Factory Of The Future And Moving Out Of The “Dark Ages”
Leaders from Axella Biosciences, Danaher Corp, McKinsey & Co and F-Prime Capital discuss the shape of things to come in biopharma manufacturing and how industry is still in the "dark ages" when it comes to batch deviations.
Scrip - September 23, 2026

FDA Should Improve Audits Of Stumbling Third-Party Review Program, GAO Says
FDA’s policies for auditing third-party reviewers lack specificity and are causing delays, says watchdog, as usage of the program continues to decline.
Medtech Insight - September 23, 2026

GLP-1-Driven Telemedicine Boom Could Undercut Economics Of Rx-To-OTC Switch
Telemedicine's role in widening access to prescription GLP-1 drugs may undercut the economic case for Rx-to-OTC switch, even as it creates a growing companion dietary supplement opportunity for consumer health companies.
HBW Insight - September 23, 2026